Despite the generic erosion of Somatuline, Ipsen is targeting +2-5% sales growth p.a. until FY24, driven by the maximisation of the value of Cabometyx, Onivyde, Palovarotene, Decapeptyl and Dysport – through label and geographic expansion. The cost-structure will also be made leaner, though SG&A efficiency gains will be reinvested to strengthen the R&D pipeline. Given the limited number of early-stage assets, €3bn has been earmarked for acquisitions, though we believe that an external growth str ....
03 Dec 2020
External innovation holds the key for long-term growth
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
External innovation holds the key for long-term growth
Despite the generic erosion of Somatuline, Ipsen is targeting +2-5% sales growth p.a. until FY24, driven by the maximisation of the value of Cabometyx, Onivyde, Palovarotene, Decapeptyl and Dysport – through label and geographic expansion. The cost-structure will also be made leaner, though SG&A efficiency gains will be reinvested to strengthen the R&D pipeline. Given the limited number of early-stage assets, €3bn has been earmarked for acquisitions, though we believe that an external growth str ....